Pioneering Scalable Single Cell RNA Sequencing: A Partnership Announced with Fluent BioSciences and Singular Genomics®

2023-11-02
PRNewswire
WATERTOWN, Mass., Nov. 2, 2023 /PRNewswire/ -- Fluent BioSciences, a cutting-edge life science company transforming single cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions, is excited to announce a partnership with Singular Genomics, a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians. Together, they unveil the compatibility of PIPseq™ Single Cell RNA Kits with sequencing on the Singular Genomics G4® Sequencing Platform.
PIPseq empowers researchers to choose the scale of their single-cell RNA sequencing experiments, from 2,000 to 100,000 cells captured per sample, without the need for microfluidics or costly instrumentation. PIPseq reactions offer unparalleled flexibility, allowing for individual or batch processing, making it an ideal choice for sporadic sample availability, complex time-course studies, or remote sample processing in less-than-ideal laboratory environments.
Complimenting PIPseq's innovation, the Singular Genomics G4 Sequencing Platform sets a new standard in benchtop sequencing. By combining cutting-edge 4-color Rapid sequencing by synthesis (SBS) chemistry with advanced engineering, the G4 Platform achieves single day turnaround times for a wide spectrum of applications. Its ability to run 1–4 flow cells in parallel, each featuring 4 independently addressable lanes, empowers laboratories to accommodate variable sample volumes and operate with maximum efficiency.
The integration of PIPseq sample preparation with the G4 Platform equips both seasoned and novice researchers with the essential tools for efficient, cost-effective, and scalable single cell analysis within any laboratory setting. An application note, available for reference, outlines the successful preparation and processing of human PBMCs in PIPseq T20 V4.0 and sequenced on the G4 Platform to give fast, high quality, and cost-efficient results.
Fluent's mission is to accelerate the understanding of single-cell biology through accessible, affordable, and scalable solutions for every researcher. Our breakthrough PIPseq™ technology enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of applications. For more information, contact [email protected].
Media Contact
Jessie Matakis
678-725-2510
[email protected]
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, Singular Genomics commenced development of the PX system, which leverages Singular's proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. Singular Genomics' mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.
Investor Contact
Matt Clawson
949-370-8500
[email protected]
Media Contact
Dan Budwick, 1AB
973-271-6085
[email protected]
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。